Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis

Fig. 1

Effects of SGLT2 inhibitors on major adverse cardiovascular events (A) and kidney composite outcomes (B) among individuals with diabetic kidney disease. CANVAS indicates Canagliflozin Cardiovascular Assessment Study, CI confidence interval, CREDENCE Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation, DECLARE‐TIMI 58 Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58, EMPA‐REG OUTCOME Empagliflozin Cardiovascular Outcome Event Trial in Type 2 diabetes Mellitus Patients, I2 I-squared, MACE major adverse cardiovascular event, NR not reported, SCORED Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk, SGLT2 sodium-glucose cotransporter 2, VERTIS CV Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840